NCT06174857

Brief Summary

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

December 8, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 18, 2023

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2025

Completed
Last Updated

December 18, 2023

Status Verified

December 1, 2023

Enrollment Period

4.5 years

First QC Date

December 8, 2023

Last Update Submit

December 8, 2023

Conditions

Advanced Non-Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (2)

  • progression-free survival

    From registration onto that step until death, or censored at the date of last contact.

    3 years

  • Overall survival

    From registration onto that step until death, or censored at the date of last contact.

    3 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

advanced or metastatic (stage IV) lung cancer

You may qualify if:

  • Patients must be ≥18 years.
  • Provision of fully informed consent prior to any study specific procedures.
  • Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
  • According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hunan Cancer hospital

Changsha, Hunan, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

needle biopsy for samples with DNA

Study Officials

  • Yongchang Zhang, MD

    Hunan Cancer Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yongchang C Zhang, MD

CONTACT

+8613873123436zhangyongchang@csu.edu.cn

Nong Yang, MD

CONTACT

+8613055193557yangnong0217@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Deputy Director of Thoracic Oncology Department

Study Record Dates

First Submitted

December 8, 2023

First Posted

December 18, 2023

Study Start

January 1, 2021

Primary Completion

June 15, 2025

Study Completion

September 15, 2025

Last Updated

December 18, 2023

Record last verified: 2023-12

Locations

CN(1)